Infant Bacterial Therapeutics
Developing microbiome therapies for premature infants to prevent life-threatening intestinal disease.
IBT | ST
Overview
Corporate Details
- ISIN(s):
- SE0008015242 (+3 more)
- LEI:
- 2138008KVBXCRJGP6Z26
- Country:
- Sweden
- Address:
- Bryggargatan 10, 111 21 Stockholm
- Website:
- https://ibtherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Infant Bacterial Therapeutics (IBT) is a pharmaceutical company dedicated to the development and commercialization of novel drugs for rare diseases affecting premature infants. The company's pipeline is focused on addressing urgent unmet medical needs, particularly the prevention of necrotizing enterocolitis (NEC), a life-threatening intestinal disease. IBT's core strategy involves developing therapies that influence the human infant microbiome. Its lead candidate, IBP-9414, is a first-in-class New Biological Entity (NBE) currently undergoing a pivotal Phase 3 clinical evaluation known as 'The Connection Study.' IBT aims to secure regulatory approval from major agencies, including the FDA and EMA, for its therapeutic products.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Infant Bacterial Therapeutics and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-20 08:00 |
Interim Report
|
Swedish | 586.0 KB | |
| 2025-08-20 08:00 |
Interim Report
|
English | 565.3 KB | |
| 2025-05-08 17:45 |
Post-Annual General Meeting Information
Annual General Meeting of Infant Bacterial Therapeutics
|
English | 41.0 KB | |
| 2025-05-08 17:45 |
Post-Annual General Meeting Information
Årsstämma i Infant Bacterial Therapeutics
|
Swedish | 40.6 KB | |
| 2025-05-07 14:30 |
Quarterly Report
|
Swedish | 550.1 KB | |
| 2025-05-07 14:30 |
Quarterly Report
|
English | 549.5 KB | |
| 2025-02-13 08:30 |
Earnings Release
|
Swedish | 577.8 KB | |
| 2025-02-13 08:30 |
Annual Report
|
English | 571.2 KB | |
| 2024-08-28 08:30 |
Interim Report
|
Swedish | 578.3 KB | |
| 2024-08-28 08:30 |
Interim Report
|
English | 594.7 KB | |
| 2024-08-15 16:44 |
Regulatory News Service
Infant Bacterial Therapeutics patent godkänt i USA
|
Swedish | 48.9 KB | |
| 2024-08-15 16:44 |
Regulatory News Service
Patent for Infant Bacterial Therapeutics has been approved in the USA
|
English | 48.4 KB | |
| 2024-07-08 16:40 |
Regulatory News Service
“The Connection Study” is completed
|
English | 52.7 KB | |
| 2024-07-08 16:40 |
Regulatory News Service
“The Connection Study” är avslutad
|
Swedish | 53.8 KB | |
| 2024-05-08 18:11 |
Post-Annual General Meeting Information
Annual General Meeting of Infant Bacterial Therapeutics
|
English | 44.2 KB |
Automate Your Workflow. Get a real-time feed of all Infant Bacterial Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Infant Bacterial Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-14 | Maria Ekdahl | Other | Buy | 500 | 17,000.00 SEK |
| 2024-02-08 | Anthon Jahreskog | Other | Buy | 839 | 79,033.80 SEK |
| 2024-02-08 | Anthon Jahreskog | Other | Buy | 161 | 15,134.00 SEK |
| 2023-06-09 | Maria Ekdahl | Other | Buy | 1,086 | 49,956.00 SEK |
| 2023-05-23 | Anders Kronström | Other | Buy | 1,329 | 56,482.50 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 851 | 36,593.00 SEK |
| 2023-05-23 | Maria Ekdahl | Other | Buy | 465 | 19,995.00 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 149 | 6,377.20 SEK |
| 2023-05-23 | Anthon Jahreskog | Other | Buy | 149 | 6,269.92 SEK |
| 2023-05-22 | Maria Ekdahl | Other | Buy | 709 | 30,487.00 SEK |
